福瑞达再度出售非主营业务资产，两大主业业绩失速

Core Viewpoint - The company, Luxshare Precision, is divesting its 100% stake in Shandong Luxshare Yintai Commercial Management Co., Ltd. to focus on its core businesses in pharmaceuticals and cosmetics, as part of its ongoing strategy to optimize resource allocation and reduce non-core operations [1][2]. Group 1: Divestiture Details - The transaction price for the divestiture is set at 88.4028 million yuan, based on the assessed value [1]. - Luxshare has previously invested 76.28 million yuan in Shandong Luxshare Yintai, which has been underperforming due to the impact of state-owned capital exiting the real estate sector [2]. Group 2: Business Performance - In 2023, the cosmetics segment generated revenue of 2.416 billion yuan, a year-on-year increase of 22.71%, with key brands like Yilian and Aier Bozhi contributing significantly [3]. - The pharmaceutical segment reported revenue of 520 million yuan in 2023, reflecting a modest growth of 1.61% [3]. Group 3: Challenges Faced - In 2024, the company experienced a decline in both revenue and net profit, with total revenue dropping to 3.983 billion yuan, a decrease of 13.02%, and net profit falling to 244 million yuan, down 19.73% [4]. - The cosmetics business growth slowed significantly, with the Aier Bozhi brand's revenue declining by 3.48% to 1.301 billion yuan in 2024 [4]. - The pharmaceutical segment also faced challenges, with revenue decreasing by 1.41% to 512 million yuan, and the raw materials and derivatives segment saw a revenue drop of 2.43% [4]. Group 4: Reasons for Revenue Decline - The company attributed the revenue decline in the pharmaceutical segment to the expansion of centralized procurement and the impact of major products like "Shipait" [5]. - In the cosmetics segment, several core products from the Aier Bozhi brand are undergoing iterations, and the brand has implemented strict pricing controls, leading to limited supply for some distributors [6].